EDEN PRAIRIE, MINN. – NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on improving surgical care for neurological disorders, has been added to the Russell Microcap Index as part of the 2026 Russell indexes reconstitution. The addition takes effect when the U.S. market opens on June 29, according to a company press release.
The Russell Microcap Index comprises the smallest 1,000 securities in the Russell 2000 Index, plus the next 1,000 smallest eligible securities by market capitalization. Inclusion in the Russell indexes is determined primarily by objective market-capitalization rankings and style attributes, as managed by FTSE Russell.
This milestone is significant for NeuroOne because the Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of June 2025, approximately $12.2 trillion in assets were benchmarked against Russell US indexes, according to FTSE Russell. Being added to the Russell Microcap Index can increase a company's visibility among institutional investors, potentially leading to greater demand for its shares and improved liquidity.
NeuroOne markets a minimally invasive and high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The semi-annual June reconstitution of the Russell US Indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for six months, automatically includes companies in the appropriate large-cap Russell 1000 or small-cap Russell 2000 indexes, as well as growth and value style indexes. For NeuroOne, being part of the Russell Microcap Index provides exposure to a broad base of investors who track these benchmarks.
For more information on the Russell Microcap Index and the reconstitution process, visit the FTSE Russell website. Additional details about NeuroOne and its products can be found at nmtc1.com.
